Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clive Grattan

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
Clinical and Translational Allergy|November 26, 2022
Pharmacokinetic equivalence of CT-P39 and reference omalizumab in healthy individuals: A randomised, double-blind, parallel-group, Phase 1 trialMarcus Maurer, Sarbjit S Saini, Kristi McLendon, et al.
Clinical and Translational Allergy|December 14, 2016
A mutually beneficial collaboration between the European Academy of Allergy and Clinical Immunology Junior Members and Clinical and Translational AllergyPeter Valentin Tomazic, Anke Graessel, Diana Silva, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 20, 2020
Hereditary Alpha-Tryptasemia: UK Prevalence and Variability in Disease ExpressionRebecca C Robey, Amy Wilcock, Hope Bonin, et al.
Clinical and Translational Allergy|December 8, 2017
Prediction and prevention of allergy and asthma in EAACI journals (2016)Jean Bousquet, Clive Grattan, Thomas Bieber, et al.
British Journal of Clinical Pharmacology|May 21, 2021
Effects of a topical treatment with spleen tyrosine kinase inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria: Results of a phase 1a/b randomised double-blind placebo-controlled studyMarion C Dickson, Alexandra Walker, Clive Grattan, et al.
Immunotherapy|February 28, 2025
Pharmacokinetics and safety of CT‑P39 via auto-injector are comparable to reference omalizumab via pre-filled syringeTomoko Hasunuma, Clive Grattan, Takashi Eto, et al.
The New England Journal of Medicine|February 26, 2013
Omalizumab for the treatment of chronic idiopathic or spontaneous urticariaMarcus Maurer, Karin Rosén, Hsin-Ju Hsieh, et al.
Clinical and Translational Allergy|February 14, 2024
A global perspective on stepping down chronic spontaneous urticaria treatment: Results of the Urticaria Centers of Reference and Excellence SDown-CSU studyMurat Türk, Emek Kocatürk, Ragıp Ertaş, et al.
Allergy|May 22, 2021
Adherence to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist in articles published in EAACI Journals: A bibliographic studyElena Wiehn, Cristian Ricci, Alberto Alvarez-Perea, et al.
The British Journal of Dermatology|March 31, 2026
The Overall Burden of Chronic Spontaneous Urticaria - The Current LandscapeEmek Kocatürk, Clive Grattan, Ivan Cherrez, et al.
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
Clinical and Translational Allergy|November 26, 2022
Pharmacokinetic equivalence of CT-P39 and reference omalizumab in healthy individuals: A randomised, double-blind, parallel-group, Phase 1 trialMarcus Maurer, Sarbjit S Saini, Kristi McLendon, et al.
Clinical and Translational Allergy|December 14, 2016
A mutually beneficial collaboration between the European Academy of Allergy and Clinical Immunology Junior Members and Clinical and Translational AllergyPeter Valentin Tomazic, Anke Graessel, Diana Silva, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 20, 2020
Hereditary Alpha-Tryptasemia: UK Prevalence and Variability in Disease ExpressionRebecca C Robey, Amy Wilcock, Hope Bonin, et al.
Clinical and Translational Allergy|December 8, 2017
Prediction and prevention of allergy and asthma in EAACI journals (2016)Jean Bousquet, Clive Grattan, Thomas Bieber, et al.
British Journal of Clinical Pharmacology|May 21, 2021
Effects of a topical treatment with spleen tyrosine kinase inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria: Results of a phase 1a/b randomised double-blind placebo-controlled studyMarion C Dickson, Alexandra Walker, Clive Grattan, et al.
Immunotherapy|February 28, 2025
Pharmacokinetics and safety of CT‑P39 via auto-injector are comparable to reference omalizumab via pre-filled syringeTomoko Hasunuma, Clive Grattan, Takashi Eto, et al.
The New England Journal of Medicine|February 26, 2013
Omalizumab for the treatment of chronic idiopathic or spontaneous urticariaMarcus Maurer, Karin Rosén, Hsin-Ju Hsieh, et al.
Clinical and Translational Allergy|February 14, 2024
A global perspective on stepping down chronic spontaneous urticaria treatment: Results of the Urticaria Centers of Reference and Excellence SDown-CSU studyMurat Türk, Emek Kocatürk, Ragıp Ertaş, et al.
Allergy|May 22, 2021
Adherence to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist in articles published in EAACI Journals: A bibliographic studyElena Wiehn, Cristian Ricci, Alberto Alvarez-Perea, et al.
The British Journal of Dermatology|March 31, 2026
The Overall Burden of Chronic Spontaneous Urticaria - The Current LandscapeEmek Kocatürk, Clive Grattan, Ivan Cherrez, et al.
Pageof 6